Cambridge Biostability joins Gates vacc adjuvant initiative

22 January 2007

UK vaccines specialist Cambridge Biostability has joined an international alliance of scientists aiming to develop a new type of vaccine which promises to deliver higher levels of protection against three of the world's most challenging diseases - malaria, tuberculosis, and AIDS. The multicenter collaboration aims to deliver safe, effective, easy-to-administer, stable vaccines which will have a significant impact on global health.

The project is funded by a grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health initiative, which was created in 2003 by the Bill & Melinda Gates Foundation and funded with $10.0 million over five years. This project focuses on incorporating into virus-vectored vaccines genes coding for molecules known to stimulate the body's natural immune system in order to create a vaccine that is able to elicit a stronger, more prolonged and, ultimately, protective immune response against the targeted disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight